Vivaldi Biosciences' Seed VC Round

Vivaldi Biosciences raised a round of funding on May 16, 2007. Investors include Bay City Capital.

Developing genetically modified vaccines to protect against common seasonal influenza and emergent pandemic influenza. Formed to commercialize patented vaccine and virus technologies developed at the…

Articles about Vivaldi Biosciences' Seed VC Round: